Brain Changes Tied to Single Psilocybin Dose; 50 Days to See Neurology; APOE4 and MS

A single 25-mg dose of psilocybin was associated with lasting anatomical brain changes, an imaging study of 28 healthy, psychedelic-naive participants showed. (Nature Communications)

A high-sensitivity digital seed amplification assay detected markers of frontotemporal lobar dementia with TDP-43 in a test of 40 cerebrospinal fluid samples. (Alzheimer’s & Dementia)

People with commercial health insurance waited an average of 50 days for their first neurology visit, a cross-sectional study found. (Neurology)

The phase II AMULET trial of investigational amlenetug in multiple system atrophy did not meet its primary endpoint, but a statistically nonsignificant finding suggested clinical progression may have slowed. (Lancet Neurology)

Accelerated continuous theta burst stimulation targeting the left primary motor cortex appeared to improve social communication in children with autism at 1 month in a trial from China. (The BMJ)

Self-reported sleep behaviors were associated with greater white matter hyperintensity volume in a prospective study of healthy U.K. Biobank participants. (Alzheimer’s & Dementia)

Prescriptions for antipsychotics and other drugs that affect cognition in older adults were more likely initiated from emergency rooms and hospitals, not doctors’ offices, research in JAMA Network Open showed.

Disability accrual from relapse-associated worsening was associated with the APOE4 allele in a cohort study of relapsing multiple sclerosis (MS) patients. (Journal of Neurology, Neurosurgery & Psychiatry)

Brain Health honored J. Craig Venter, PhD, the genomicist whose earliest breakthroughs began at the National Institute of Neurological Disorders and Stroke, who died last week at age 79.